Clinical Trials · NCT00877890
A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 254
- Start date
- Mar 2009
- Locations
- 41 sites, United States
- Primary endpoint
- Change in HbA1c From Baseline to Week 24